Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30, 2025".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported H1FY26 revenue of ₹1,501 Mn, up 10.2% YoY, with PAT surging 39.2% YoY to ₹234 Mn and PAT margins expanding 324 bps to 15.6%. Q2FY26 revenue was nearly flat at ₹745 Mn (-0.3% YoY) due to temporary moderation from the GST 2.0 transition, but PAT grew 9.7% YoY to ₹126 Mn with margins improving 154 bps to 16.9%. Operating EBITDA for H1FY26 stood at ₹338 Mn (+8.8% YoY) at a 22.5% margin, while the company holds a strong cash balance of ₹1,604 Mn post a 125% dividend payout of ₹166 Mn. Management appointed Amrut Medhekar as COO and Nirav Vora as CFO, and outlined a three-pronged growth strategy of new product launches (4-6 annually), volume growth via sales force empowerment, and price increases, coupled with inorganic growth through brand and business acquisitions.
Strong H1 profitability and PAT margin expansion signal solid operational execution, but flat Q2 revenue and slight EBITDA margin compression (-31 to -39 bps) due to GST transition may temper near-term sentiment. Robust cash position, debt-free balance sheet, and active inorganic growth strategy are positive for long-term shareholders.